Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Other Operating Expenses (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Other Operating Expenses data on record, last reported at $25.8 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 128.9% year-over-year to $25.8 million; the TTM value through Dec 2025 reached $68.9 million, down 58.02%, while the annual FY2025 figure was $68.9 million, 58.02% down from the prior year.
  • Other Operating Expenses reached $25.8 million in Q4 2025 per MRVI's latest filing, up from -$78.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $77.1 million in Q3 2024 and bottomed at -$117.0 million in Q4 2023.
  • Average Other Operating Expenses over 5 years is $23.2 million, with a median of $37.8 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 1161.59% in 2021, then plummeted 202.01% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $11.2 million in 2021, then surged by 239.37% to $38.2 million in 2022, then tumbled by 406.45% to -$117.0 million in 2023, then surged by 109.64% to $11.3 million in 2024, then skyrocketed by 128.9% to $25.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $25.8 million in Q4 2025, -$78.7 million in Q3 2025, and $70.2 million in Q2 2025.